Last reviewed · How we verify
paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin
paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin is a HCV protease inhibitor / NS5A inhibitor / polymerase inhibitor combination Small molecule drug developed by American Research Corporation. It is currently FDA-approved for Chronic hepatitis C virus (HCV) infection, genotypes 1a and 1b, with or without cirrhosis, HCV genotype 1 infection in treatment-naïve and treatment-experienced patients.
This combination inhibits hepatitis C virus (HCV) replication by blocking multiple viral enzymes essential for viral protein processing and RNA synthesis.
This combination inhibits hepatitis C virus (HCV) replication by blocking multiple viral enzymes essential for viral protein processing and RNA synthesis. Used for Chronic hepatitis C virus (HCV) infection, genotypes 1a and 1b, with or without cirrhosis, HCV genotype 1 infection in treatment-naïve and treatment-experienced patients.
At a glance
| Generic name | paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin |
|---|---|
| Sponsor | American Research Corporation |
| Drug class | HCV protease inhibitor / NS5A inhibitor / polymerase inhibitor combination |
| Target | HCV NS3/4A protease, NS5A protein, NS5B polymerase |
| Modality | Small molecule |
| Therapeutic area | Virology / Hepatology |
| Phase | FDA-approved |
Mechanism of action
Paritaprevir is an NS3/4A protease inhibitor that prevents viral polyprotein cleavage; ritonavir is a pharmacokinetic booster that increases paritaprevir levels; ombitasvir is an NS5A inhibitor that disrupts viral RNA replication; and dasabuvir is an NS5B polymerase inhibitor that blocks viral RNA synthesis. Together, these agents target distinct steps in the HCV replication cycle, achieving high cure rates across multiple HCV genotypes.
Approved indications
- Chronic hepatitis C virus (HCV) infection, genotypes 1a and 1b, with or without cirrhosis
- HCV genotype 1 infection in treatment-naïve and treatment-experienced patients
Common side effects
- Fatigue
- Headache
- Nausea
- Pruritus
- Asthenia
- Elevated bilirubin
Key clinical trials
- Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment (PHASE4)
- A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (PHASE3)
- Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P (PHASE3)
- A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (PHASE3)
- Study of Oral Treatments for Hepatitis C (PHASE4)
- Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy (PHASE2)
- A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects (PHASE2, PHASE3)
- DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO) (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin CI brief — competitive landscape report
- paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin updates RSS · CI watch RSS
- American Research Corporation portfolio CI
Frequently asked questions about paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin
What is paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin?
How does paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin work?
What is paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin used for?
Who makes paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin?
What drug class is paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin in?
What development phase is paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin in?
What are the side effects of paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin?
What does paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin target?
Related
- Drug class: All HCV protease inhibitor / NS5A inhibitor / polymerase inhibitor combination drugs
- Target: All drugs targeting HCV NS3/4A protease, NS5A protein, NS5B polymerase
- Manufacturer: American Research Corporation — full pipeline
- Therapeutic area: All drugs in Virology / Hepatology
- Indication: Drugs for Chronic hepatitis C virus (HCV) infection, genotypes 1a and 1b, with or without cirrhosis
- Indication: Drugs for HCV genotype 1 infection in treatment-naïve and treatment-experienced patients
- Compare: paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin vs similar drugs
- Pricing: paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin cost, discount & access